SH Healthcare Investment No.1 Association Plans OTC Sale of 785,559 Rights to Subscribe to NGeneBio Rights Offering to Secure Subscription Funds
The largest shareholder of NGeneBio, SH Healthcare Investment No.1 Association, reported a plan on July 10, 2026 to sell 785,559 subscription rights certificates in an OTC transaction.
The proceeds will be used to finance the exercise of remaining rights in the company's rights offering, with the expected sale amount being approximately 2.46 billion KRW.
Following the transaction, the shareholder's ownership will decline from 33.62% to 28.26%.
[AI Summary]This OTC sale of subscription rights is a funding measure by the major shareholder to participate in the rights offering, directly causing no dilution but the disposal size of 8% of outstanding shares may affect market supply and demand.
KOSDAQ Filing Information
Report On Transaction Plan Of Specific Securities By Executives And Major Shareholders
Company: NGeneBio (354200)
Submission: SH Healthcare Investment No.1 Association